Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Company’s Drug Development Pipeline
COLORADO SPRINGS, Colo., May 29, 2013 /PRNewswire/ — Cannabis Science, Inc. (NASD OTC: CBIS), announced today the appointment of clinical development expert, Dr. Dorothy Bray, Ph.D., as Chief Executive Officer and Director.
Dr. Bray served as Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit in the UK. She also held various positions of responsibility at GlaxoSmithKline as Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline, as Senior Medical Strategy Head, International Medical Affairs, Glaxo Wellcome Inc, USA, and as Principal Clinical Research Scientist at Antivirals, Glaxo Wellcome, UK and USA.
“While it has been an honor and a privilege to hold the position of CEO in Cannabis Science during early development phase, the Company has grown dramatically and now requires a CEO with the experience and expertise that Dr. Bray unquestionably has. I am excited to remain as President and see her take the lead as the Company’s new CEO. I think this strategic move will greatly accelerate our drug development program and bring CS-TATI-1 to the millions of HIV infected people around the world in need of this valuable addition to the world’s pharmacopeia,” said Dr. Robert Melamede, President and Director of Cannabis Science.
Dr. Bray is IMMUNOCLIN’s founder, holds an honorary Senior Lecturer position at the Royal Free School of Medicine, University of London, and acts as the European Commission’s Scientific Expert. Dr. Bray has significant expertise in clinical development and market positioning for novel drugs. She has a track record of bringing scientific discoveries to market and acts as a business advisor to a number of biotechnology companies.
Dr. Bray’s extensive experience in the field of HIV drug development will lead Cannabis Science along with the prestigious Scientific Advisory Board as the company embarks on the research and development of a phytocannabinoid based HIV TAT inhibitors.
“Cannabis Science has an impressive team. I am proud to be given the privilege of joining the Board and being asked to lead as Chief Executive Officer. I look forward to working with the team and progressing to achieve the company goals set forth,” stated Dr. Dorothy Bray, Ph.D., CEO & Director of Cannabis Science.
Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment-experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of Federal Research Programs such as RO1s, PO1s and SBIRs, which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
About Cannabis Science, Inc.
Cannabis Science, Inc. is conducting cannabinoid-based therapeutic research and development to address neglected pandemic oncological manifestations of pandemic infectious diseases in human health. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize other therapeutic approaches to antiviral and antibacterial innovation. Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-TATI-1 topical cannabinoid-based preparations for the treatment of Kaposi’s Sarcoma, basal and squamous cell carcinomas and HIV Tat inhibition.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Vice President of Investor Relations
SOURCE Cannabis Science, Inc.